Teveten - Instructions For The Use Of Tablets, Analogs, Reviews, Price

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Teveten

Teveten: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacodynamics and pharmacokinetics
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. With impaired renal function
10. 10. Drug interactions
11. 11. Analogs
12. 12. Terms and conditions of storage
13. 13. Terms of dispensing from pharmacies
14. 14. Reviews
15. 15. Price in pharmacies

Latin name: Teveten

ATX code: C09CA02

Active ingredient: Eprosartan (Eprosartan)

Producer: ABBOTT HEALTHCARE PRODUCTS (Netherlands)

Description and photo update: 2019-05-08

Prices in pharmacies: from 300 rubles.

Buy

Teveten is a drug with a vasodilating, antihypertensive and indirectly diuretic effect.

Release form and composition

• coated tablets, 400 mg each: color - light pink, shape - oval, biconvex, engraving on one side - "5044", on the other - SOLVAY (in blisters of 14 pcs., in a cardboard box 1, 2 or 4 blister);
• film-coated tablets, 600 mg each: color - white, shape - oval, biconvex, engraving on one side - "5046", on the other - SOLVAY (in blisters of 14 pcs., in a cardboard box 1, 2 or 4 blisters).

Composition of 1 tablet, film-coated and film-coated:

• active substance: eprosartan - 400 or 600 mg (eprosartan mesylate - 490.55 or 735.8 mg);
• auxiliary components (400/600 mg, respectively): microcrystalline cellulose - 179.05 / 43.3 mg; lactose monohydrate - 28.75 / 43.3 mg; gelatinized corn starch - 28.75 / 43.3 mg; crospovidone - 32 / 38.5 mg; magnesium stearate - 6 / 7.2 mg, purified water - 34.9 / 50.9 mg;
• shell (400/600 mg, respectively): Opadry pink (YS-1-14643-A) / Opadry white (OY-S-9603) - 32 / 38.5 mg.

Pharmacodynamics and pharmacokinetics

Teveten is an antihypertensive agent belonging to the group of angiotensin type 2 receptor blockers.

Eprosartan is characterized by a selective effect on the AT1-type receptors located in the adrenal glands, kidneys, blood vessels, heart, and the formation of a strong connection with them, followed by slow dissociation.

Angiotensin type 2 binds to AT1 receptors in many tissues, which causes hypertrophy of the muscle tissue of the heart and blood vessels, the retention of sodium ions and the release of aldosterone, as well as narrowing of the vascular lumen.

Eprosartan inhibits or prevents the development of the effects of type 2 angiotensin, inhibiting the functioning of the renin-angiotensin-aldosterone system. This substance has a vasodilating and hypotensive effect. Its oral administration leads to a weakening of arterial vasoconstriction, a decrease in peripheral vascular resistance and pressure in the pulmonary circulation, a decrease in the reabsorption of fluid and sodium ions in the renal tubules. Long-term therapy with Teveten helps to reduce the proliferative properties of type 2 angiotensin, which are reflected in the state of vascular and myocardial smooth muscle cells.

After taking a standard dose of the drug, the hypotensive effect lasts throughout the day, and a noticeable therapeutic effect with regular use is recorded 15-20 days later, and there are no pulse rate fluctuations.

Taking the first dose of Teveten does not lead to the development of orthostatic hypotension.

When using the drug in patients with arterial hypertension, there is no change in the concentration of glucose, triglycerides, total cholesterol or LDL-C, which is determined in fasting blood plasma. Eprosartan enhances renal blood flow and accelerates glomerular filtration, inhibiting the excretion of albumin. The substance does not affect purine metabolism or renal excretion of uric acid.

In patients undergoing therapy with Teveten, the incidence of dry cough is 1.5%. When treatment is stopped, there is no withdrawal syndrome. Eprosartan does not inhibit the enzymes 2A6, 3A, CYP1A, 2C9 / 8, 2C19, 2D6 and 2E of cytochrome P ₄₅₀.

With a single oral administration of Teveten at a dose of 300 mg, the bioavailability of the active substance of the drug is 13%. The maximum content of eprosartan in plasma is reached after 1-2 hours. When taking the drug simultaneously with food, there are slight decreases in maximum concentration and absorption, which are not clinically significant.

Plasma protein binding is 98%. The half-life of eprosartan is approximately 7-9 hours. The substance is excreted mainly in feces (about 90%) and urine (about 7%). Less than 2% of the dose taken is excreted from the body through the kidneys in the form of glucuronides.

The degree of interaction with blood proteins does not depend on the presence of compensated renal failure, liver dysfunctions, gender and age, but may decrease in the case of severe forms of renal failure.

Indications for use

Teveten is prescribed for the treatment of hypertension.

Contraindications

Absolute:

• severe arterial stenosis of a single functioning kidney or hemodynamically significant bilateral renal artery stenosis;
• combined use with aliskiren and drugs containing aliskiren in patients with diabetes mellitus or moderate / severe renal dysfunction (glomerular filtration rate less than 60 ml / min / 1.73 m ²);
• lactase deficiency of Lapps (Sami), galactose intolerance, glucose-galactose malabsorption syndrome (the drug contains lactose monohydrate);
• age up to 18 years (the safety profile for this group of patients has not been studied);
• pregnancy and lactation;
• established individual intolerance to the components of the drug.

Relative (the appointment of Theveten requires caution in the presence of the following diseases / conditions):

• chronic heart failure in severe course (NYHA functional class IV);
• a decrease in the volume of circulating blood and / or excessive excretion of sodium from the body (including disorders associated with vomiting, diarrhea, taking diuretics in high doses);
• stenosis of an artery of a single kidney or bilateral stenosis of the renal arteries;
• stenosis of the mitral and aortic valves;
• hypertrophic obstructive cardiomyopathy;
• ischemic heart disease (due to limited experience of use);
• liver failure, including patients on hemodialysis and patients with creatinine clearance less than 30 ml / min (due to limited experience of use);
• Negroid race.

There are no data on the safety of Teveten's use in patients with recent kidney transplantation.

When planning a pregnancy, women should switch to taking alternative drugs with antihypertensive effects, which are approved for use during pregnancy, except in cases where continued Teveten is necessary. After confirmation of pregnancy, the drug is immediately canceled.

Instructions for use of Teveten: method and dosage

The tablets are taken orally, regardless of the meal.

It is possible to use the drug as monotherapy or in combination with other drugs with antihypertensive action.

The recommended daily dose is 1 tablet once a day.

The maximum dose is 600 mg per day.

In most cases, the greatest therapeutic effect is observed after 2–3 weeks of therapy.

The daily dose for moderate / severe renal failure (with creatinine clearance less than 60 ml / min) and liver failure is not more than 600 mg.

Side effects

The most common adverse reactions: headache and nonspecific complaints about the state of the digestive system.

Possible disorders observed during therapy (very often -> 1/10; often -> 1/100, 1/1000, 1/10 000, <1/1000; very rarely - <1/10 000):

• cardiovascular system: infrequently - a pronounced decrease in blood pressure;
• respiratory system: often - rhinitis;
• immune system: infrequently - hypersensitivity reactions;
• digestive system: often - nonspecific complaints about the state of the digestive system (in the form of nausea, diarrhea, vomiting);
• central nervous system: very often - headache; often - asthenia, dizziness;
• skin and subcutaneous fat: often - allergic skin reactions (in the form of skin rash, itching); infrequently - angioedema (including lips, pharynx, face, tongue).

With the post-registration use of Teveten, the development of disorders of the genitourinary system (with an unknown frequency) was noted: impaired renal function, including renal failure in patients at risk (for example, with renal artery stenosis).

Overdose

Overdose symptoms are dehydration and electrolyte imbalance, manifested in the form of nausea and drowsiness, as well as a sharp drop in blood pressure.

Depending on the time that has passed after taking Teveten, overdose treatment includes the intake of enterosorbents and gastric lavage. In case of pronounced arterial hypotension, it is advisable to give the patient a horizontal position and raise his legs, and, if necessary, infuse plasma-substituting fluids. The appointment of supportive and symptomatic therapy is recommended. The use of hemodialysis is recognized as ineffective.

special instructions

Before using Teveten, as well as periodically during the course, patients with renal failure need to monitor the functional state of the kidneys. If it worsens, it is necessary to re-evaluate the feasibility of taking the drug.

When used in combination with potassium-sparing diuretics, food supplements / substitutes for table salt containing potassium and other drugs that can increase serum potassium in the blood (for example, with heparin), an increase in serum potassium may be observed (such combinations require caution) … Monitoring of this indicator is recommended for patients who are at risk.

According to the instructions, Teveten should not be used in conjunction with angiotensin-converting enzyme inhibitors in patients with diabetic nephropathy.

Double blockade of the renin-angiotensin system by the combined use of angiotensin-converting enzyme inhibitors, Teveten or aliskiren is not recommended, since this can lead to the development of arterial hypotension, hyperkalemia and impaired renal function (including acute renal failure). In cases where double blockade is extremely necessary, it must be carried out strictly under the supervision of a physician, constantly monitoring kidney function, blood pressure and electrolyte content.

With primary aldosteronism, the use of Teveten is not recommended.

During the period of the therapeutic course, it is recommended to be careful when driving vehicles and performing potentially hazardous types of work, which is associated with the likelihood of developing weakness and dizziness.

With impaired renal function

In patients whose renal function is associated with the activity of the renin-angiotensin-aldosterone system (for example, with renal artery stenosis of a single kidney, bilateral renal artery stenosis, or severe heart failure), progressive azotemia and / or oliguria may develop during therapy with ACE inhibitors, and occasionally acute renal failure.

Drug interactions

With the combined use of eprosartan with certain drugs / substances, the following effects may develop:

• potassium-sparing diuretics, dietary supplements / salt substitutes with potassium content, other drugs that can increase blood potassium (for example, heparin): increase in serum potassium in the blood;
• angiotensin-converting enzyme inhibitors, aliskiren (double blockade of the renin-angiotensin system): increased incidence of adverse reactions such as arterial hypotension, hyperkalemia and decreased renal function (including acute renal failure);
• other drugs with hypotensive action: potentiation of the Teveten effect;
• angiotensin-converting enzyme inhibitors: a reversible increase in the serum lithium content in the blood, the development of toxic reactions (it is required to monitor lithium in the blood plasma);
• nonsteroidal anti-inflammatory drugs: an increased risk of deterioration of renal function, including the likelihood of acute renal failure, and an increase in serum potassium in the blood, especially against the background of already existing renal dysfunction (the combination requires caution, especially in elderly patients; volume replacement is recommended therapy and monitoring of renal function after the start of the combined use of these drugs and periodically during the course).

Analogs

Teveten's analogues are: Eprosartan, Naviten, Edarbi, Advant, Sentor, Aprovel, Pulsar, Vazar, Praitor, Valeza, Nortivan, Valsakor, Mikardis, Kandekor, Lorista, Kandesar, Lozap, Kantab, Cardosal.

Terms and conditions of storage

Store in a dry place at temperatures up to 25 ° C. Keep out of the reach of children.

Shelf life:

• coated tablets, 400 mg - 2 years;
• film-coated tablets, 600 mg - 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Teveten

According to reviews, Teveten is well tolerated by patients, has a pronounced therapeutic effect and does not lead to serious side effects. However, the use of the drug is limited due to the relatively high cost and insufficient prevalence in the network of pharmacies.

Price for Teveten in pharmacies

The price for Teveten 600 mg in pharmacies varies in the range of 1200-1400 rubles (the package includes 14 tablets). Tablets of the drug 400 mg are not currently available for sale.

Teveten: prices in online pharmacies

Drug name Price Pharmacy

Teveten Plus 12.5 mg + 600 mg film-coated tablets 14 pcs. RUB 300 Buy

Teveten 600 mg film-coated tablets 14 pcs. 1172 RUB Buy

Teveten tablets p.p. 600mg 14 pcs. 1495 RUB Buy

Teveten Plus 12.5 mg + 600 mg film-coated tablets 28 pcs. 1690 RUB Buy

Teveten Plus tablets p.o. 600mg + 12.5mg 28 pcs. 1956 RUB Buy

Teveten tablets p.p. 600mg 28 pcs. 2632 RUB Buy

Teveten 600 mg film-coated tablets 28 pcs. 2632 RUB Buy

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!